Monoclonal Antibodies Stanford Academia-Industry Collaboration

Description: experiences moving his discovery from the lab to the clinical setting and discusses the future of this cancer treatment. Wendy Harpham, a participant in the early clinical trials of Rituxan, the first FDA-approved monoclonal antibody for cancer treatment that Levy developed, provides a patient's perspective. Stanford University School of Medicine: med.stanford.edu Stanford University Channel on YouTube: www.youtube.com ... medicine health disease therapy treatment research immune system ...